BioMate is the computational platform for organizations doing hard biomedical science at scale — pharma, biotech, CROs, and the clinical teams that run their trials. One environment. Every discipline. Audit‑ready by default.
The hardest scientific questions today are answered by people working across institutions, disciplines, and time zones. A genomics team at a university, a DMPK group at a pharma partner, a CRO running the assays — rarely one organization, rarely one tool.
BioMate's vision is to be the computational layer that makes that collaboration tractable: where results arrive structured and reproducible, where the methods are visible to everyone who needs them, and where the next team's work starts from the same defensible foundation the last team built.
Every team doing serious biomedical work hits the same wall: the questions that matter most take too long to answer, cost too much to run, and produce results no one else can re‑use.
BioMate exists to invert that. Questions get answered faster. Outputs arrive already structured, quality‑assessed and ready for the next team — not just the team that ran them.
BioMate was founded in late 2025 by a team with deep roots in biomedical informatics and NLP. The founding insight was simple: the bottleneck in computational life science is not capability — it is access. The tools exist. The methods are published. What is missing is a platform that makes them usable by the scientists who need them, without requiring a computational specialist at every step.
We built the platform the way the science demanded: evidence-grounded, auditable, and broad enough to cover the full span of computationally demanding biomedical work — from genomics and structural biology to drug discovery, clinical pharmacology, and regulatory documentation.
Every result on BioMate is defensible — by design, not by documentation.
Today BioMate is in production with pilot teams across pharma, biotech, CROs, and academic medical centers — 2,000+ validated workflows, 20+ domains, and a quality framework that regulatory reviewers and journal editors can inspect at the parameter level.
| Founded | Late 2025 |
|---|---|
| Headquarters | Houston, Texas — Texas Medical Center |
| Platform type | AI-powered computational biology SaaS |
| Validated workflows | 2,455+ across 34 biological domains |
| Key integrated tools | GATK, DeepVariant, STAR, salmon, Seurat, AlphaFold 2/3, CryoSPARC, AutoDock Vina, GROMACS, DESeq2, MaxQuant, QIIME 2 |
| Pricing | Free — no card required; Pro $49/mo; Team $199/mo; Enterprise — contact sales |
| Compliance | HIPAA-compliant; BAA available; private VPC deployment option |
| Data policy | Your data is never used to train shared AI models; tenant-isolated workspace |
Not aspirational statements. The constraints we apply when deciding what to build, what to charge, and what to refuse.
BioMate integrates the gold‑standard methods your teams already rely on — not alternatives or approximations. Same tools. New coordination layer.